Twist Bioscience (TWST) CAO sells 167 shares in mandated tax sell-to-cover
Rhea-AI Filing Summary
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, sold 167 shares of common stock on 2026-08-03 at $85.3212 per share. According to the company’s equity incentive plans, this mandated “sell to cover” transaction funded tax withholding on vesting Restricted Stock Units and was not discretionary. Following the sale, Werner directly held 46,160 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 167 shares
Net Sell
1 txn
Insider
WERNER ROBERT F.
Role
Chief Accounting Officer
Sold
167 shs ($14K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 167 | $85.3212 | $14K |
Holdings After Transaction:
Common Stock — 46,160 shares (Direct)
Footnotes (1)
- F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Key Figures
Shares sold: 167 shares
Sale price per share: $85.3212 per share
Post-transaction holdings: 46,160 shares
3 metrics
Shares sold
167 shares
Common stock sold on 2026-08-03 in a mandated sell-to-cover
Sale price per share
$85.3212 per share
Price received for the 167 common shares sold
Post-transaction holdings
46,160 shares
Directly owned Twist Bioscience common stock after the sale
Key Terms
Restricted Stock Units, sell to cover, equity incentive plans, tax withholding obligations
4 terms
Restricted Stock Units financial
"in connection with the vesting of Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"funded by a "sell to cover" transaction and do not represent"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
equity incentive plans financial
"under its equity incentive plans to require the satisfaction"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
tax withholding obligations financial
"sold by the Reporting Person to cover tax withholding obligations"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock transaction did TWST report for Robert F. Werner?
Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 167 shares of common stock at $85.3212 per share. The 2026-08-03 sale was a mandated sell-to-cover to satisfy tax withholding on vesting Restricted Stock Units, rather than a discretionary trade.
Was the TWST insider sale by Robert F. Werner a discretionary trade?
No. The filing states the 167 shares sold by Robert F. Werner were required to cover tax withholding obligations tied to Restricted Stock Unit vesting. These “sell to cover” transactions are mandated under Twist Bioscience’s equity incentive plans and are not discretionary trades by the officer.
Does the TWST Form 4 mention a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not affirmed, and a pre-arranged trading plan is not cited. Instead, the footnote explains the 167-share sale was mandated under Twist Bioscience’s equity incentive plans solely to satisfy tax withholding from Restricted Stock Unit vesting.